Enhancing the anti-angiogenic action of histone deacetylase inhibitors
2007

Combining Histone Deacetylase Inhibitors with Interferon for Cancer Treatment

publication 10 minutes Evidence: moderate

Author Information

Author(s): Kuljaca Selena, Liu Tao, Tee Andrew EL, Haber Michelle, Norris Murray D, Dwarte Tanya, Marshall Glenn M

Primary Institution: The Children's Cancer Institute Australia for Medical Research, The University of New South Wales

Hypothesis

The combination of histone deacetylase inhibitors (HDACIs) and interferon (IFNα) will enhance anti-cancer effects compared to either treatment alone.

Conclusion

The combination of TSA and IFNα therapy has potent co-operative cytotoxic and anti-angiogenic activity.

Supporting Evidence

  • TSA and IFNα were the most effective combination across a range of different cancer cell lines.
  • Normal non-malignant cells did not respond in the same manner to the combination therapy.
  • Inhibition of p21WAF1 expression increased the cytotoxic effects of TSA and IFNα.
  • TSA and IFNα co-operatively inhibited gene expression of pro-angiogenic factors in neuroblastoma cells.
  • The combination therapy markedly reduced tumour angiogenesis in neuroblastoma-bearing transgenic mice.

Takeaway

Using two cancer-fighting drugs together can work better than using them alone, especially for certain types of cancer.

Methodology

The study involved in vitro assays on various cancer cell lines and in vivo experiments on transgenic mice to assess the effects of TSA and IFNα.

Limitations

The study primarily focused on specific cancer cell lines and may not generalize to all cancer types.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1186/1476-4598-6-68

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication